Literature DB >> 1650014

[Chemotherapy of non-small cell bronchial cancers. Meta-analysis of the literature as a function of the extent of the disease].

N Donnadieu1, M Paesmans, J P Sculier.   

Abstract

A meta-analysis was carried out on the studies of chemotherapy of non small cell bronchial cancer published over the last fifteen years and this has demonstrated that the initial extent of the tumour was a significant prognostic factor in the response to treatment. A total of 6,247 patients were eligible for analysis: 1,435 with limited disease and 4,812 with disseminated disease. The objective and complete response levels for the overall group for those with limited disease and those with disseminated disease were respectively 25 and 3%, 34 and 5% and 22 and 3%. These differences were highly significant. The response level was significantly lower in cases of monotherapy when compared to combinations of cytostatic agents. In polychemotherapy, it was those combinations containing cisplatin, vindesine, vinblastine, mitomycin C and ifosfamide which were associated with the best results. An elevated dose of cisplatin (greater than or equal to 100 mg/m2) was also associated with a better response than those on the lower dose (less than or equal to 70 mg/m2). These differences were most clearly shown in those with limited disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1650014

Source DB:  PubMed          Journal:  Rev Mal Respir        ISSN: 0761-8425            Impact factor:   0.622


  4 in total

Review 1.  Respiratory diseases.

Authors:  D G James
Journal:  Postgrad Med J       Date:  1992-03       Impact factor: 2.401

2.  The role of mitomycin in the treatment of non-small cell lung cancer: a systematic review with meta-analysis of the literature.

Authors:  J P Sculier; L Ghisdal; T Berghmans; F Branle; J J Lafitte; F Vallot; A P Meert; F Lemaitre; E Steels; A Burniat; C Mascaux
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

3.  Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.

Authors:  J P Sculier; J J Lafitte; M Paesmans; J Thiriaux; C G Alexopoulos; J Baumöhl; J Schmerber; G Koumakis; M C Florin; C Zacharias; T Berghmans; P Mommen; V Ninane; J Klastersky
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

4.  Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.

Authors:  J L Pujol; A Monnier; J Berille; M L Cerrina; J Y Douillard; A Rivière; A Grandgirard; S Gouva; J P Bizzari; T Le Chevalier
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.